pharma · Renal Transplantation · Rheumatoid Arthritis (RA)
Astellas Pharma
Astellas Pharma Inc
NovaPharmaNews editorial coverage mentioning Astellas Pharma — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 20
- Drugs
- 12
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning Astellas Pharma — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Astellas Pharma — regulatory, clinical, and market analysis.
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
Fierce Pharma Asia: Key Insights on Recent Deals and Trends
This article provides a comprehensive overview of the latest developments in the pharmaceutical industry, focusing on Pfizer's $10B Innovent deal and Astellas' strategic roadmap.
Astellas Cuts Costs Amid FDA Review of Moderna Vaccine
Astellas Pharma is implementing cost reductions as the FDA panel prepares to review the Moderna vaccine. This article explores the implications for the pharmaceutical industry.